Do certain signal transduction mechanisms explain the comorbidity of epilepsy and mood disorders?

Epilepsy and Behavior

Volumn 38, Issue , 2014, Pages 25-31

  Rocha, Luisa ^a   Alonso Vanegas, Mario ^b   Orozco Suárez, Sandra ^c   Alcántara González, David ^a   Cruzblanca, Humberto ^d   Castro, Elena ^d  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c Century XXI   (Mexico)

^d UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

Anxiety; Depression; G protein; Heterodimers; Homodimers; Receptors; Second messengers; Temporal lobe epilepsy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR; HETERODIMER; HOMODIMER; SEROTONIN 1A RECEPTOR;

ANTICONVULSANT THERAPY; COMORBIDITY; DOPAMINE BLOOD LEVEL; EPILEPSY; HUMAN; MOOD DISORDER; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION; REVIEW; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; METABOLISM; MOOD DISORDERS; PHYSIOLOGY;

COMORBIDITY; EPILEPSY; HUMANS; MOOD DISORDERS; SIGNAL TRANSDUCTION;

EID: 84910598427     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.01.001     Document Type: Review

References (127)

1. Kanner A.M. Depression and epilepsy: a bidirectional relation?. Epilepsia 2011, 52:21-27.
2. Briellmann R.S., Hopwood M.J., Jackson G.D. Major depression in temporal lobe epilepsy with hippocampal sclerosis: clinical and imaging correlates. J Neurol Neurosurg Psychiatry 2007, 78:1226-1230.
3. Gonçalves E.B., Cendes F. Depression in patients with refractory temporal lobe epilepsy. Arq Neuropsiquiatr 2011, 69:775-777.
4. Kanner A.M. Epilepsy, depression and anxiety disorders: a complex relation with significant therapeutic implications for the three conditions. J Neurol Neurosurg Psychiatry 2013, 84:e1.
5. Avissar S., Schreiber G. Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol Med 2002, 8:294-300.
6. Bowen D.M., Najlerahim A., Procter A.W., Francis P.T., Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci U S A 1989, 86:9504-9508.
7. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999, 46:1375-1387.
8. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007, 34:865-877.
9. Savitz J.B., Drevets W.C. Neuroreceptor imaging in depression. Neurobiol Dis 2013, 52:49-65.
10. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998, 43:547-573.
11. Meijer O.C., Van Oosten R.V., de Kloet E.R. Elevated basal trough levels of corticosterone suppress hippocampal 5-HT1A receptor expression in adrenally intact rats: implication for the pathogenesis of depression. Neuroscience 1997, 80:419-426.
12. Stockmeier C.A., Howley E., Shi X., Sobanska A., Clarke G., Friedman L., et al. Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. J Psychiatr Res 2009, 43:887-894.
13. Toczek M.T., Carson R.E., Lang L., Ma Y., Spanaki M.V., Der M.G., et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003, 60:749-756.
14. Savic I., Lindstrom P., Gulyas B., Halldin C., Andree B., Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004, 62:1343-1351.
15. Rocha L., Lorigados-Pedre L., Orozco-Suárez S., Morales-Chacón L., Alonso-Vanegas M., García-Maeso I., et al. Autoradiography reveals selective changes in serotonin binding in neocortex of patients with temporal lobe epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1208-1218.
16. Hasler G., Bonwetsch R., Giovacchini G., Toczek M.T., Bagic A., Luckenbaugh D.A., et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62:1258-1264.
17. Theodore W.H., Hasler G., Giovacchini G., Kelley K., Reeves-Tyer P., Herscovitch P., et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007, 48:1526-1530.
18. Theodore W.H., Wiggs E.A., Martinez A.R., Dustin I.H., Khan O.I., Appel S., et al. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia 2012, 53:129-133.
19. Merlet I., Ostrowsky K., Costes N., Ryvlin P., Isnard J., Faillenot I., et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain 2004, 127:900-913.
20. Nowak G., Dulinski J. Effect of repeated treatment with electroconvulsive shock (ECS) on serotonin receptor density and turnover in the rat cerebral cortex. Pharmacol Biochem Behav 1991, 38:691-694.
21. de Montigny C. Electroconvulsive treatments enhance responsiveness of forebrain neurons to serotonin. J Pharmacol Exp Ther 1984, 228:230-234.
22. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998, 18:10150-10156.
23. 1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol 1996, 119:813-818.
24. Wada Y., Nakamura M., Hasegawa Y., Yamaguchi N. Intra-hippocampal injection of 8-hidroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) inhibits partial and generalized seizures induced by kindling stimulation in cats. Neurosci Lett 1993, 159:179-182.
25. López-Meraz M.L., González-Trujano M.E., Neri-Bazán L., Hong E., Rocha L.L. 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats. Neuropharmacology 2005, 49:367-375.
26. López-Meraz M.L., Martínez A., Rocha L. Effect of 8-OH-DPAT on electrographic activity during the kainic acid-induced status epilepticus in rats. Seizure 2007, 16:365-370.
27. Bean A.J., Roth R.H. Effects of haloperidol administration on in vivo extracellular dopamine in striatum and prefrontal cortex after partial dopamine lesions. Brain Res 1991, 549:155-158.
28. Espejo E.F. Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Brain Res 1997, 762:281-284.
29. Johnson M.R., Lydiard R.B., Zealberg J.J., Fossey M.D., Ballenger J.C. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry 1994, 36:425-427.
30. Tiihonen J., Kuikka J., Bergström K., Lepola U., Koponen H., Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997, 154:239-242.
31. Schneier F.R., Liebowitz M.R., Abi-Dargham A., Zea-Ponce Y., Lin S.H., Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 2000, 157:457-459.
32. Schneier F.R., Martinez D., Abi-Dargham A., Zea-Ponce Y., Simpson H.B., Liebowitz M.R., et al. Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 2008, 25:1-7.
33. Dougherty D.D., Bonab A.A., Ottowitz W.E., Livni E., Alpert N.M., Rauch S.L., et al. Decreased striatal D1 binding as measured using PET and [11C]Sch 23,390 in patients with major depression with anger attacks. Depress Anxiety 2006, 23:175-177.
34. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002, 52:740-748.
35. D'Haenen H.A., Bossuyt A. Dopamine D receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994, 35:128-132.
36. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997, 27:1247-1256.
37. Lehto S.M., Kuikka J., Tolmunen T., Hintikka J., Viinamäki H., Vanninen R., et al. Temporal cortex dopamine D2/3 receptor binding in major depression. Psychiatry Clin Neurosci 2008, 62:345-348.
38. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol Psychiatry 1992, 32:1-17.
39. Willner P. Dopamine and depression: a review of recent evidence. II: Theoretical approaches. Brain Res 1983, 287:225-236.
40. Kobayashi K., Haneda E., Higuchi M., Suhara T., Suzuki H. Chronic fluoxetine selectively upregulates dopamine D1-like receptors in the hippocampus. Neuropsychopharmacology 2012, 37:1500-1508.
41. Taoka H., Hamamura T., Endo S., Miki M., Lee Y., Miyata S., et al. G(olf) protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy. Life Sci 2006, 79:462-468.
42. Klimek V., Maj J. Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2-receptors. J Pharm Pharmacol 1989, 41:555-558.
43. Rogoz R., Dziedzicka-Wasylevska M. Effects of antidepressant drugs on the dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol 1999, 359:178-186.
44. Hirvonen J., Hietala J., Kajander J., Markkula J., Rasi-Hakala H., Salminen J.K., et al. Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol 2011, 25:1329-1336.
45. Landau A.M., Chakravarty M.M., Clark C.M., Zis A.P., Doudet D.J. Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 2011, 36:511-518.
46. 11C]FLB 457. J Clin Psychiatry 2010, 71:793-799.
47. Werhahn K.J., Landvogt C., Klimpe S., Buchholz H.G., Yakushev I., Siessmeier T., et al. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study. Epilepsia 2006, 47:1392-1396.
48. Rocha L., Alonso-Vanegas M., Villeda-Hernández J., Mújica M., Cisneros-Franco J.M., López-Gómez M., et al. Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy. Neurobiol Dis 2012, 45:499-507.
49. Bonci A., Hopf F.W. The dopamine D2 receptor: new surprises from an old friend. Neuron 2005, 47:335-338.
50. Breuer M.E., Groenink L., Oosting R.S., Buerger E., Korte M., Ferger B., et al. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol 2009, 616:134-140.
51. Hermann B.P., Wyler A.R. Depression, locus of control, and the effects of epilepsy surgery. Epilepsia 1989, 30:332-338.
52. Jackson M.J., Turkington D. Depression and anxiety in epilepsy. J Neurol Neurosurg Psychiatry 2005, 76(Suppl. 1):45-47.
53. Levinson A.J., Fitzgerald P.B., Favalli G., Blumberger D.M., Daigle M., Daskalakis Z.J. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010, 67:458-464.
54. Bielau H., Steiner J., Mawrin C., Trübner K., Brisch R., Meyer-Lotz G., et al. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci 2007, 1096:157-169.
55. Kalueff A.V., Nutt D.J. Role of GABA in anxiety and depression. Depress Anxiety 2007, 24:495-517.
56. Petty F., Kramer G.L., Gullion C.M., Rush A.J. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry 1992, 32:354-363.
57. Nikolaus S., Antke C., Müller H.W. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res 2009, 204:32-66.
58. Cheetham S.C., Crompton M.R., Katona C.L., Parker S.J., Horton R.W. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 1988, 460:114-123.
59. Stocks G.M., Cheetham S.C., Crompton M.R., Katona C.L., Horton R.W. Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims. J Affect Disord 1990, 18:11-15.
60. Kugaya A., Sanacora G., Verhoeff N.P., Fujita M., Mason G.F., Seneca N.M., et al. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biol Psychiatry 2003, 54:792-799.
61. Abadie P., Boulenger J.P., Benali K., Barré L., Zarifian E., Baron J.C. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. Eur J Neurosci 1999, 11:1470-1478.
62. Klumpers U.M., Veltman D.J., Drent M.L., Boellaard R., Comans E.F., Meynen G., et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010, 37:565-574.
63. Malizia A.L., Cunningham V.J., Bell C.J., Liddle P.F., Jones T., Nutt D.J. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998, 55:715-720.
64. Mombereau C., Kaupmann K., Froestl W., Sansig G., van der Putten H., Cryan J.F. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety and antidepressant-like behavior. Neuropsychopharmacology 2004, 29:1050-1062.
65. Cryan J.F., Slattery D.A. GABAB receptors and depression. Current status. Adv Pharmacol 2010, 58:427-451.
66. Enna S.J., Bowery N.G. GABAB receptor alterations as indicators of physiological and pharmacological function. Biochem Pharmacol 2004, 68:1541-1548.
67. Lloyd K.G., Thuret F., Pilc A. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 1985, 235:191-199.
68. Breslow M.F., Fankhauser M.P., Potter R.L., Meredith K.E., Misiaszek J., Hope D.G. Role of gamma-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry 1989, 146:353-356.
69. Drake R.G., Davis L.L., Cates M.E., Jewell M.E., Ambrose S.M., Lowe J.S. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 2003, 37:1177-1181.
70. Esel E., Kose K., Hacimusalar Y., Ozsoy S., Kula M., Candan Z., et al. The effects of electroconvulsive therapy on GABAergic function in major depressive patients. J ECT 2008, 24:224-228.
71. During M.J., Ryder K.M., Spencer D.D. Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature 1995, 376:174-177.
72. Avoli M., Louvel J., Drapeau C., Pumain R., Kurcewicz I. GABAA-mediated inhibition and in vitro epileptogenesis in the human neocortex. J Neurophysiol 1995, 73:468-484.
73. DeFelipe J. Chandelier cells and epilepsy. Brain 1999, 122:1807-1822.
74. Hammers A., Koepp M.J., Labbé C., Brooks D.J., Thom M., Cunningham V.J., et al. Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy. Neurology 2001, 56:897-906.
75. Koepp M.J., Hammers A., Labbé C., Woermann F.G., Brooks D.J., Duncan J.S. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. Neurology 2000, 54:332-339.
76. la Fougère C., Rominger A., Förster S., Geisler J., Bartenstein P. PET and SPECT in epilepsy: a critical review. Epilepsy Behav 2009, 15:50-55.
77. Hoogland G., Blomenröhr M., Dijstelbloem H., de Wit M., Spierenburg H.A., van Veelen C.W., et al. Characterization of neocortical and hippocampal synaptosomes from temporal lobe epilepsy patients. Brain Res 1999, 837:55-66.
78. Van Gelder N.M., Sherwin A.L., Rasmussen T. Amino acid content of epileptogenic human brain: focal versus surrounding regions. Brain Res 1972, 40:385-393.
79. Sherwin A.L., van Gelder N.M. Amino acid and catecholamine markers of metabolic abnormalities in human focal epilepsy. Adv Neurol 1986, 44:1011-1032.
80. Labiner D.M., Yan C.C., Weinand M.E., Huxtable R.J. Distubances of amino acids from temporal lobe synaptosomes in human complex partial epilepsy. Neurochem Res 1999, 24:1379-1383.
81. Perry Tl, Hansen S., Kennedy J., Wada J.A., Thompson G.B. Amino acids in human epileptogenic foci. Arch Neurol 1975, 32:752-754.
82. Hamberger A., Nyström B., Larsson S., Silfvenius H., Nordborg C. Amino acids in the neuronal microenvironment of focal human epileptic lesions. Epilepsy Res 1991, 9:32-43.
83. Burdette D.E., Sakurai S.Y., Henry T.R., Ross D.A., Pennell P.B., Frey K.A., et al. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy. Neurology 1995, 45:934-941.
84. Palomero-Gallagher N., Schleicher A., Bidmon H.J., Pannek H.W., Hans V., Gorji A., et al. Multireceptor analysis in human neocortex reveals complex alterations of receptor ligand binding in focal epilepsies. Epilepsia 2012, 53:1987-1997.
85. Zilles K., Qü M.S., Köhling R., Speckmann E.J. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience 1999, 94:1051-1061.
86. Sata Y., Matsuda K., Mihara T., Aihara M., Yagi K., Yonekura Y. Quantitative analysis of benzodiazepine receptor in temporal lobe epilepsy: [(125)I]iomazenil autoradiographic study of surgically resected specimens. Epilepsia 2002, 43:1039-1048.
87. Hobbs W.R., Rall T.W., Verdoorn R.A. Hypnotics and sedatives; ethanol. Goodman and Gillman's The pharmacological basis of therapeutics 1996, 361-396. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon (Eds.).
88. Croarkin P.E., Levinson A.J., Daskalakis Z.J. Evidence for GABAergic inhibitory deficits in major depressive disorder. Neurosci Biobehav Rev 2011, 35:818-825.
89. Mangan P.S., Lothman E.W. Profound disturbances of pre- and postsynaptic GABAB-receptor-mediated processes in region CA1 in a chronic model of temporal lobe epilepsy. J Neurophysiol 1996, 76:1282-1296.
90. Pacheco M.A., Stockmeier C., Meltzer H.Y., Overholser J.C., Dilley G.E., Jope R.S. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 1996, 723:37-45.
91. Friedman E., Wang H.Y. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 1996, 67:1145-1152.
92. González-Maeso J., Meana J.J. Heterotrimeric g proteins: insights into the neurobiology of mood disorders. Curr Neuropharmacol 2006, 4:127-138.
93. García-Sevilla J.A., Walzer C., Busquets X., Escribá P.V., Balant L., Guimón J. Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biol Psychiatry 1997, 42:704-712.
94. Karege F., Bovier P., Stepanian R., Malafosse A. The effect of clinical outcome on platelet G proteins of major depressed patients. Eur Neuropsychopharmacol 1998, 8:89-94.
95. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
96. Perez J., Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R. Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disord 2000, 2:27-36.
97. Stewart R.J., Chen B., Dowlatshahi D., MacQueen G.M., Young L.T. Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Res Bull 2001, 55:625-629.
98. Gould T.D., Manji H.K. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002, 53:687-697.
99. Cowburn R.F., Marcusson J.O., Eriksson A., Wiehager B., O'Neill C. Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 1994, 633:297-304.
100. Lowther S., Crompton M.R., Katona C.L., Horton R.W. GTP gamma S and forskolin-stimulated adenylyl cyclase activity in post-mortem brain from depressed suicides and controls. Mol Psychiatry 1996, 1:470-477.
101. Valdizán E.M., Gutierrez O., Pazos A. Adenylate cyclase activity in postmortem brain of suicide subjects: reduced response to beta-adrenergic stimulation. Biol Psychiatry 2003, 54:1457-1464.
102. McGowan S., Eastwood S.L., Mead A., Burnet P.W., Smith C., Flanigan T.P., et al. Hippocampal and cortical G protein (Gs alpha, G(o) alpha and Gi2 alpha) mRNA expression after electroconvulsive shock or lithium carbonate treatment. Eur J Pharmacol 1996, 306:249-255.
103. Lasoń W., Przewłocki R. Seizure-induced expression of G proteins in the rat hippocampus. Brain Res Mol Brain Res 1994, 24:65-69.
104. Iwasa H., Kikuchi S., Mine S., Sugita K., Miyagishima H., Hasegawa S. Functional significance of stimulatory GTP-binding protein in hippocampus is associated with kindling-elicited epileptogenesis. Psychiatry Clin Neurosci 2000, 54:191-197.
105. Cuellar-Herrera M., Velasco A.L., Velasco F., Chavez L., Orozco-Suarez S., Armagan G., et al. Mu opioid receptor mRNA expression, binding, and functional coupling to G-proteins in human epileptic hippocampus. Hippocampus 2012, 22:122-127.
106. DeFelipe J., Marco P., Sola R.G., Sánchez-Blázquez P., Garzón J. Local changes in GTP-binding protein immunoreactivities in human epileptogenic neocortex. Exp Brain Res 1998, 119:153-158.
107. Ludvig N., Moshé S.L. Different behavioral and electrographic effects of acoustic stimulation and dibutyryl cyclic AMP injection into the inferior colliculus in normal and in genetically epilepsy-prone rats. Epilepsy Res 1989, 3:185-190.
108. Ludvig N., Mishra P.K., Jobe P.C. Dibutyryl cyclic AMP has epileptogenic potential in the hippocampus of freely behaving rats: a combined EEG-intracerebral microdialysis study. Neurosci Lett 1992, 141:187-191.
109. Higashima M., Ohno K., Koshino Y. Cyclic AMP-mediated modulation of epileptiform afterdischarge generation in rat hippocampal slices. Brain Res 2002, 949:157-161.
110. Yokoyama N., Mori N., Kumashiro H. Chemical kindling induced by cAMP and transfer to electrical kindling. Brain Res 1989, 492:158-162.
111. Chen G., Pan B., Hawver D.B., Wright C.B., Potter W.Z., Manji H.K. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996, 67:2079-2086.
112. Rocha L., Orozco-Suarez S., Alonso-Vanegas M., Villeda-Hernandez J., Gaona A., Páldy E., et al. Temporal lobe epilepsy causes selective changes in mu opioid and nociceptin receptor binding and functional coupling to G-proteins in human temporal neocortex. Neurobiol Dis 2009, 35:466-473.
113. Poat J.A., Cripps H.E., Iversen L.L. Differences between high-affinity forskolin binding sites in dopamine-rich and other regions of rat brain. Proc Natl Acad Sci U S A 1988, 85:3216-3220.
114. Stratinaki M., Varidaki A., Mitsi V., Ghose S., Magida J., Dias C., et al. Regulator of G protein signaling is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci U S A 2013, 110:8254-8259.
115. Chen Y., Liu Y., Cottingham C., McMahon L., Jiao K., Greengard P., et al. Neurabin scaffolding of adenosine receptor and RGS4 regulates anti-seizure effect of endogenous adenosine. J Neurosci 2012, 32:2683-2695.
116. Fuxe K., Marcellino D., Guidolin D., Woods A.S., Agnati L.F. Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. Physiology (Bethesda) 2008, 23:322-332.
117. Fuxe K., Marcellino D., Borroto-Escuela D.O., Frankowska M., Ferraro L., Guidolin D., et al. The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J Recept Signal Transduct Res 2010, 30:272-283.
118. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 2003, 24:346-354.
119. Albizu L., Moreno J.L., González-Maeso J., Sealfon S.C. Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets 2010, 9:636-650.
120. Agnati L.F., Ferré S., Lluis C., Franco R., Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003, 55:509-550.
121. Pei L., Li S., Wang M., Diwan M., Anisman H., Fletcher P.J., et al. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 2010, 16(12):1393-1395.
122. Wong A.H., Liu F. Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment. Clin Pharmacol Ther 2012, 91:298-302.
123. Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lança A.J., et al. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 2004, 279:35671-35678.
124. Rashid A.J., So C.H., Kong M.M., Furtak T., El-Ghundi M., Cheng R., et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 2007, 104:654-659.
125. Hasbi A., Fan T., Alijaniaram M., Nguyen T., Perreault M.L., O'Dowd B.F., et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 2009, 106:21377-21382.
126. Renner U., Zeug A., Woehler A., Niebert M., Dityatev A., Dityateva G., et al. Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J Cell Sci 2012, 125:2486-2499.
127. Mombereau C., Kaupmann K., Gassmann M., Bettler B., van der Putten H., Cryan J.F. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 2005, 16:307-310.